Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca, atugen Enter Validation, Drug-Discovery Alliance

NEW YORK, Oct. 16 – German biotech company atugen and AstraZeneca plan to use atugen’s GeneBloc technology to enhance target validation and drug development in an undisclosed number of “major disease areas” of interest to AstraZeneca.

Terms of the deal call for Berlin-based atugen to retain all rights to specific GeneBlocs it develops for the drugs giant and will have an option to license certain intellectual property generated in the collaboration, according to a statement.

AstraZeneca, in turn, will have the opportunity to expand into a multiyear collaboration a one-year agreement both firms signed in August 1999 that seeks to validate their libraries of genomic targets.

Financial details of the deal were not disclosed.

"It is our expectation that atugen's antisense technology will play an important role in the process of selecting gene targets of therapeutic value from the thousands of novel genes recently discovered and in further validation of gene targets already of interest,” John Stageman, vice president of Enabling Science and Technologies at AstraZeneca said in the statement. “Use of this technology should result in lower attrition rates and important savings in time and research costs for AstraZeneca."

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.